FDA approves Celgene's Thalomid for myeloma

Celgene has received an approvable letter from the FDA to expand the use of Thalomid for multiple myeloma. The letter typically indicates that a drug developer will need to submit additional information before final approval is given. Thalomid is approved for leprosy but is often used off-label for cancer.

- read this AP report for more

Suggested Articles

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes. 

NeoTX Therapeutics has nabbed a healthy $45 million third funding round as it looks to continue work on its early-stage cancer combo test.

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.